Literature DB >> 20067919

Activation of Rho GTPases in Smith-Lemli-Opitz syndrome: pathophysiological and clinical implications.

Xiao-Sheng Jiang1, Christopher A Wassif, Peter S Backlund, Li Song, Lynne A Holtzclaw, Zheng Li, Alfred L Yergey, Forbes D Porter.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a malformation syndrome with neurocognitive deficits due to mutations of DHCR7 that impair the reduction of 7-dehydrocholesterol to cholesterol. To investigate the pathological processes underlying the neurocognitive deficits, we compared protein expression in Dhcr7(+/+) and Dhcr7(Delta3-5/Delta3-5) brain tissue. One of the proteins identified was cofilin-1, an actin depolymerizing factor which regulates neuronal dendrite and axon formation. Differential expression of cofilin-1 was due to increased phosphorylation. Phosphorylation of cofilin-1 is regulated by Rho GTPases through Rho-Rock-Limk-Cofilin-1 and Rac/Cdc42-Pak-Limk-Cofilin-1 pathways. Pull-down assays were used to demonstrate increased activation of RhoA, Rac1 and Cdc42 in Dhcr7(Delta3-5/Delta3-5) brains. Consistent with increased activation of these Rho GTPases, we observed increased phosphorylation of both Limk and Pak in mutant brain tissue. Altered Rho/Rac signaling impairs normal dendritic and axonal formation, and mutations in genes encoding regulators and effectors of the Rho GTPases underlie other human mental retardation syndromes. Thus, we hypothesized that aberrant activation of Rho/Rac could have functional consequences for dendrite and axonal growth. In vitro analysis of Dhcr7(Delta3-5/Delta3-5) hippocampal neurons demonstrated both axonal and dendritic abnormalities. Developmental abnormalities of neuronal process formation may contribute to the neurocognitive deficits found in SLOS and may represent a potential target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20067919      PMCID: PMC2838542          DOI: 10.1093/hmg/ddq011

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

Review 1.  Rho GTPases in neuronal morphogenesis.

Authors:  L Luo
Journal:  Nat Rev Neurosci       Date:  2000-12       Impact factor: 34.870

2.  Rho GTPases regulate distinct aspects of dendritic arbor growth in Xenopus central neurons in vivo.

Authors:  Z Li; L Van Aelst; H T Cline
Journal:  Nat Neurosci       Date:  2000-03       Impact factor: 24.884

3.  Probability-based protein identification by searching sequence databases using mass spectrometry data.

Authors:  D N Perkins; D J Pappin; D M Creasy; J S Cottrell
Journal:  Electrophoresis       Date:  1999-12       Impact factor: 3.535

4.  Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16.

Authors:  H Daub; K Gevaert; J Vandekerckhove; A Sobel; A Hall
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

5.  Two novel mutations confirm FGD1 is responsible for the Aarskog syndrome.

Authors:  C E Schwartz; G Gillessen-Kaesbach; M May; M Cappa; J Gorski; K Steindl; G Neri
Journal:  Eur J Hum Genet       Date:  2000-11       Impact factor: 4.246

6.  Abnormal spine morphology and enhanced LTP in LIMK-1 knockout mice.

Authors:  Yanghong Meng; Yu Zhang; Vitali Tregoubov; Christopher Janus; Luis Cruz; Mike Jackson; Wei Yang Lu; John F MacDonald; Jay Y Wang; Douglas L Falls; Zhengping Jia
Journal:  Neuron       Date:  2002-07-03       Impact factor: 17.173

7.  Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith--Lemli--Opitz syndrome.

Authors:  C A Wassif; P Zhu; L Kratz; P A Krakowiak; K P Battaile; F F Weight; A Grinberg; R D Steiner; N A Nwokoro; R I Kelley; R R Stewart; F D Porter
Journal:  Hum Mol Genet       Date:  2001-03-15       Impact factor: 6.150

8.  The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism.

Authors:  J P Labrador; V Azcoitia; J Tuckermann; C Lin; E Olaso; S Mañes; K Brückner; J L Goergen; G Lemke; G Yancopoulos; P Angel; C Martínez; R Klein
Journal:  EMBO Rep       Date:  2001-05       Impact factor: 8.807

9.  Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome.

Authors:  E Tierney; N A Nwokoro; F D Porter; L S Freund; J K Ghuman; R I Kelley
Journal:  Am J Med Genet       Date:  2001-01-15

10.  7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome.

Authors:  B U Fitzky; F F Moebius; H Asaoka; H Waage-Baudet; L Xu; G Xu; N Maeda; K Kluckman; S Hiller; H Yu; A K Batta; S Shefer; T Chen; G Salen; K Sulik; R D Simoni; G C Ness; H Glossmann; S B Patel; G S Tint
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

View more
  20 in total

Review 1.  Malformation syndromes caused by disorders of cholesterol synthesis.

Authors:  Forbes D Porter; Gail E Herman
Journal:  J Lipid Res       Date:  2010-10-07       Impact factor: 5.922

2.  Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome.

Authors:  G J Patti; L P Shriver; C A Wassif; H K Woo; W Uritboonthai; J Apon; M Manchester; F D Porter; G Siuzdak
Journal:  Neuroscience       Date:  2010-07-27       Impact factor: 3.590

3.  Desmosterol in brain is elevated because DHCR24 needs REST for Robust Expression but REST is poorly expressed.

Authors:  G S Tint; Luxing Pan; Quan Shang; Laura J Sharpe; Andrew J Brown; Man Li; Hongwei Yu
Journal:  Dev Neurosci       Date:  2014-05-24       Impact factor: 2.984

4.  DHCEO accumulation is a critical mediator of pathophysiology in a Smith-Lemli-Opitz syndrome model.

Authors:  Libin Xu; Karoly Mirnics; Aaron B Bowman; Wei Liu; Jennifer Da; Ned A Porter; Zeljka Korade
Journal:  Neurobiol Dis       Date:  2011-12-11       Impact factor: 5.996

5.  Spontaneously regressing brain lesions in Smith-Lemli-Opitz syndrome.

Authors:  An N Dang Do; Eva H Baker; Katherine E Warren; Simona E Bianconi; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2017-12-11       Impact factor: 2.802

6.  Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype.

Authors:  Asya L Borikova; Christopher F Dibble; Noah Sciaky; Christopher M Welch; Amy N Abell; Sompop Bencharit; Gary L Johnson
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

7.  An oxysterol biomarker for 7-dehydrocholesterol oxidation in cell/mouse models for Smith-Lemli-Opitz syndrome.

Authors:  Libin Xu; Zeljka Korade; Dale A Rosado; Wei Liu; Connor R Lamberson; Ned A Porter
Journal:  J Lipid Res       Date:  2011-03-14       Impact factor: 5.922

8.  Quantitative proteomics analysis of inborn errors of cholesterol synthesis: identification of altered metabolic pathways in DHCR7 and SC5D deficiency.

Authors:  Xiao-Sheng Jiang; Peter S Backlund; Christopher A Wassif; Alfred L Yergey; Forbes D Porter
Journal:  Mol Cell Proteomics       Date:  2010-03-19       Impact factor: 5.911

9.  Rho GTPases RhoA and Rac1 mediate effects of dietary folate on metastatic potential of A549 cancer cells through the control of cofilin phosphorylation.

Authors:  Natalia V Oleinik; Kristi L Helke; Emily Kistner-Griffin; Natalia I Krupenko; Sergey A Krupenko
Journal:  J Biol Chem       Date:  2014-08-01       Impact factor: 5.157

10.  Altered cerebrospinal fluid proteins in Smith-Lemli-Opitz syndrome patients.

Authors:  Stephanie M Cologna; Christine Shieh; Cynthia L Toth; Antony Cougnoux; Kathryn R Burkert; Simona E Bianconi; Christopher A Wassif; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2016-05-05       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.